25892-94-8

Basic information

• Product Name: 1-(4-(benzyloxy)-3,6-dihydroxy-2-Methoxyphenyl)ethanone
• Synonyms: 1-(4-(benzyloxy)-3,6-dihydroxy-2-Methoxyphenyl)ethanone;1-(4-(benzyloxy)-3,6-dihydroxy-2-methoxyphenyl)ethan-1-one
• CAS NO: 25892-94-8
• Molecular Formula: C₁₆H₁₆O₅
• Molecular Weight: 288.29524
• Mol File: 25892-94-8.mol

Chemical Properties

• Melting Point: 161-162 °C
• Boiling Point: 517.6±50.0 °C(Predicted)
• Appearance: /
• Density: 1.272±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 9.37±0.50(Predicted)
• CAS DataBase Reference: 1-(4-(benzyloxy)-3,6-dihydroxy-2-Methoxyphenyl)ethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-(benzyloxy)-3,6-dihydroxy-2-Methoxyphenyl)ethanone(25892-94-8)
• EPA Substance Registry System: 1-(4-(benzyloxy)-3,6-dihydroxy-2-Methoxyphenyl)ethanone(25892-94-8)

Safety Data

• Hazardous Substances Data: 25892-94-8(Hazardous Substances Data)

Usage

Preparation

Obtained from 4-(benzyloxy)-2-hydroxy-6- methoxy-acetophenone by persulfate oxidation (Elbs reaction).

Upstream product

• 39548-89-5 1-(4-(benzyloxy)-2-hydroxy-6-methoxyphenyl)ethan-1-one 
• 90-24-4 2-hydroxy-4,6-dimethoxyacetophenone 
• 480-66-0 2,4,6-trihydroxyacetophenone 
• 3602-54-8 4,6-dihydroxy-2-methoxyacetophenone 
• 77-98-5 tetraethylammonium hydroxide 
• 100-39-0 benzyl bromide 
• 480-40-0 5,7-dihydroxy-2-phenyl-chromen-4-one 
• 110506-85-9 7-(benzyloxy)-5-hydroxy-2-phenyl-4H-chromen-4-one 
• 681294-57-5 1-(4-(benzyloxy)-2-hydroxy-6-methoxyphenyl)ethanone 

Downstream Products

• 25893-02-1 7-benzyloxy-5,6-dimethoxy-2-(4-methoxy-phenyl)-chromen-4-one 
• 25892-95-9 1-(4-(benzyloxy)-6-hydroxy-2,3-dimethoxyphenyl)ethan-1-one 
• 1447-88-7 hispidulin 
• 480-11-5 oroxylin A 
• 520-12-7 pectolinarigenin 
• 40983-99-1 2-(3,4-dimethoxyphenyl)-7-hydroxy-5,6-dimethoxy-4H-chromen-4-one 
• 22368-21-4 eupatilin 
• 52378-70-8 (E)-1-(4-Benzyloxy-6-hydroxy-2,3-dimethoxy-phenyl)-3-(3,4-dimethoxy-phenyl)-propenone 
• 52378-71-9 7-(benzyloxy)-2-(3,4-dimethoxyphenyl)-6,7-dimethoxy-4H-chromen-4-one 

Relevant articles and documents

Novel compound and composition for prevention, improvement or treatment of fibrosis or non-alcoholic steatohepatitis comprising the same

The present invention relates to a novel compound and a composition for prevention, improvement, or treatment of fibrosis or nonalcoholic steatohepatitis comprising the same as an active ingredient. More specifically, the present invention relates to a novel compound of chemical formula 1 which has an excellent effect for prevention, improvement, or treatment of fibrosis and a composition for prevention, improvement, or treatment of fibrosis or nonalcoholic steatohepatitis comprising the same as an active ingredient. A novel compound of the present invention effectively controls expression of snail and vimentin which are a controlling element of Epithelial Mesenchymal Transition (EMT) and controls activation of EMT, and thus effectively prevents, improves, or treats fibrosis accordingly. Additionally, a novel compound of the present invention has a very excellent pharmacokinetic characteristic, and thus can perform fast drug delivery to the body through oral administration, stably displays an effect in the body, and is secure to use without a big side effect. Moreover, since a novel compound of the present invention can effectively block fibrosis of a hepatic cell, nonalcoholic steatohepatitis can effectively improved or treated.(AA) Chemical formula 1COPYRIGHT KIPO 2018

USE OF CHROMONE DERIVATIVE AS PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF FIBROSIS USING EMT INHIBITORY ACTIVITY

A pharmaceutical composition contains the chromone derivative of Chemical Formula 1 and a pharmaceutically acceptable salt as an active ingredient, thus effectively inhibiting the activation of EMT to thereby enable the effective suppression of a disease caused by fibrosis of an organ or tissue in vivo due to the activation of EMT.

The flavone hispidulin, a benzodiazepine receptor ligand with positive allosteric properties, traverses the blood-brain barrier and exhibits anticonvulsive effects

1 The functional characterization of hispidulin (4′,5,7-trihydroxy-6- methoxyflavone), a potent benzodiazepine (BZD) receptor ligand, was initiated to determine its potential as a modulator of central nervous system activity. 2 After chemical synthesis, hispidulin was investigated at recombinant GABA A/BZD receptors expressed by Xenopus laevis oocytes. Concentrations of 50 nM and higher stimulated the GABA-induced chloride currents at tested receptor subtypes (α 1-3,5,6β2γ2S) indicating positive allosteric properties. Maximal stimulation at α1β 2γ2S was observed with 10 μM hispidulin. In contrast to diazepam, hispidulin modulated the α6β 2γ2S-GABAA receptor subtype. 3 When fed to seizure-prone Mongolian gerbils (Meriones unguiculatus) in a model of epilepsy, hispidulin (10 mg kg-1 body weight (BW) per day) and diazepam (2 mg kg-1 BW per day) markedly reduced the number of animals suffering from seizures after 7 days of treatment (30 and 25% of animals in the respective treatment groups, vs 80% in the vehicle group). 4 Permeability across the blood-brain barrier for the chemically synthesized, 14C-labelled hispidulin was confirmed by a rat in situ perfusion model. With an uptake rate (Kin) of 1.14 ml min-1 g -1, measurements approached the values obtained with highly penetrating compounds such as diazepam. 5 Experiments with Caco-2 cells predict that orally administered hispidulin enters circulation in its intact form. At a concentration of 30 μM, the flavone crossed the monolayer without degradation as verified by the absence of glucuronidated metabolites.

Gastroprotective flavone/flavanone compounds with therapeutic effect on inflammatory bowel disease

PCT No. PCT/KR97/00144 Sec. 371 Date Jan. 14, 1999 Sec. 102(e) Date Jan. 14, 1999 PCT Filed Jul. 25, 1997 PCT Pub. No. WO98/04541 PCT Pub. Date Feb. 5, 1998The present invention relates to novel flavone/flavanone compounds or their pharmaceutically acceptable salts and process for preparation thereof for protecting gastrointestinal tracts against gastritis, ulcers and inflammatory bowel disease.